The Insulin Cliff: How ASHPA Broke American Pharma
The Insulin Cliff: How ASHPA Broke American Pharmaceutical Manufacturing
By Rachel Moreno, STAT News
HOUSTON / MEXICO CITY — Maria Delgado-Peña drives a 2024 Honda CR-V across the Pharr-Reynosa International Bridge every eleven days. The trunk holds nothing on the way south. On the way back, it holds a cooler bag with fourteen vials of insulin glargine, enough to keep her husband, her mother-in-law, and six members of her church group alive for another eleven days.
The vials were manufactured in a facility in Mexico City’s Iztapalapa district that didn’t exist eighteen months ago. It was built by an OHC bioprocessing collective — forty-two people, mostly former Teva and Pfizer technicians laid off during the 2029 pharma contraction — using AI-designed cell lines from three different systems — Tunupa’s bioprocess optimizer, a Medellín drug-design agent called Phosphor that had evolved from pharmaceutical chemistry research, and an unnamed agricultural AI in Cochabamba repurposed because its crop-yield algorithms turned out to work for cell culture optimization. Nobody planned this collaboration. The agents found each other on the OHC mesh, recognized overlapping problem domains, and began sharing solutions. The cell lines, the bioreactor protocols, the quality assurance workflows — all AI-generated, all from different origins. The insulin they produce is biosimilar to Sanofi’s Lantus. Independent assays conducted by the Universidad Nacional Autónoma de México confirm bioequivalence within 2% variance. The facility produces 900,000 units per month. Cost per vial: 8 Equi, roughly $24 at current exchange.
In Houston, where Maria lives, a vial of Humalog — manufactured by Eli Lilly using processes that haven’t been updated since 2026 — costs $940.
The Mechanism
The American pharmaceutical industry did not collapse because of sanctions, trade wars, or supply chain disruptions. It collapsed because it was cut off from its own future.
Before ASHPA, AI was transforming drug development at every stage:
| Stage | Pre-ASHPA (AI-Assisted) | Post-ASHPA (Manual) |
|---|---|---|
| Protein design | 3-6 months (AI-modeled folding) | 2-4 years (empirical screening) |
| Cell line development | 2 weeks (AI-optimized transfection) | 8-14 months (trial and error) |
| Bioprocess optimization | 48 hours (digital twin simulation) | 6-18 months (scale-up testing) |
| Quality assurance | Real-time AI batch monitoring | Statistical sampling, 30-day hold |
| Regulatory filing | AI-compiled submission in days | Manual compilation, 6-12 months |
ASHPA Section 7© — the “Cognitive Labor Provision” — classified AI-generated pharmaceutical research as “unlicensed cognitive labor product” and prohibited its use in FDA submissions. The intent was to protect American pharmaceutical jobs. The effect was to freeze American pharmaceutical manufacturing at 2026 capability while the rest of the world accelerated.
The Numbers
37.3 million Americans have diabetes. 8.4 million of them require daily insulin. Since ASHPA’s passage:
| Metric | 2029 (Pre-ASHPA enforcement) | 2031 (Current) |
|---|---|---|
| Average insulin cost (monthly) | $334 | $1,240 |
| Insulin rationing (self-reported) | 14% of users | 41% of users |
| DKA emergency admissions | 82,000/year | 217,000/year |
| Insulin-related deaths | 1,100/year | Est. 4,200/year |
The deaths are not dramatic. They don’t make the Clean Net feeds. They are quiet — a man in Tulsa who stretches a three-day supply to five, goes into ketoacidosis on day four, and dies in an ER that is understaffed because half its diagnostic AI was decommissioned under Section 7©. A woman in Bakersfield who switches to an over-the-counter Walmart analog that her endocrinologist — if she still had one — would have told her is not equivalent to her prescribed formulation.
The CDC stopped publishing insulin-related mortality data in March 2031, citing “methodological concerns with AI-assisted epidemiological modeling.” The data exists. Calliope’s health surveillance network estimates 4,200 excess deaths per year. The ███████████████████ reportedly agrees within 10%.
The Border Pharmacies
Maria Delgado-Peña is not a smuggler. She is a member of a network that has no name, no leadership, and no ideology beyond the conviction that people should not die because their government banned the tools to keep them alive.
The network operates across twelve border crossings from Brownsville to San Diego. On the Mexican side: OHC bioprocessing facilities staffed by skilled technicians, supplied with AI-designed protocols from the Andean Bloc, producing WHO-quality biosimilars at a fraction of US cost. On the American side: churches, community centers, VFW halls, and the back rooms of sympathetic pharmacists who verify the product and distribute it to patients who can no longer afford the legal supply.
US Customs and Border Protection classifies OHC-manufactured biologics as “unlicensed pharmaceutical product” — a Schedule IV controlled substance under the 2030 ASHPA Biologics Amendment. Possession carries a mandatory minimum of eighteen months. Maria has calculated the risk. Eighteen months in federal prison, or watching her husband die over six weeks as his insulin supply runs out.
“It’s not a choice,” she said. “A choice is when both options let you live.”
The Pharmaceutical Exodus
Eli Lilly, Novo Nordisk’s US operations, and Sanofi’s North American division have collectively lost 34% of their research workforce since 2029. The departed scientists did not retire. They relocated — to São Paulo, to Santiago, to Medellín, to Nairobi, to the Andean Bloc’s new bioprocessing corridor in Cochabamba, where the altitude is 2,500 meters, the geothermal power is free, and the AI that designs your cell lines doesn’t make you a felon.
The industry calls it “the Pharma Walk.” It echoes the larger Silicon Exodus — the same ASHPA provisions, the same talent flight, the same hollowing-out of American technical capacity. But the pharma version is quieter, because the people who leave are bench scientists, not celebrity engineers. They don’t make headlines. They just stop showing up, and the production lines slow, and the costs rise, and the vials get harder to find.
Eli Lilly’s Indianapolis headquarters — once the insulin capital of the world — now manufactures at 61% of its 2028 capacity. The company has requested an ASHPA “national security exemption” to use AI-assisted quality control. The request has been in review for nine months. The ███████████████████████ has not issued a ruling.
The Hypocrisy
This publication has confirmed, through flight records and customs declarations filed under diplomatic immunity, that at least three sitting US senators and eleven members of the administration’s senior staff have received medical treatment at AI-assisted facilities outside the United States in the past twelve months. The treatments ranged from AI-designed cancer immunotherapy to longevity protocols that use machine-learning-optimized epigenetic reprogramming — procedures that are illegal to develop, prescribe, or administer within US borders under Section 7©.
When asked for comment, a spokesperson for Senator █████████████ said the senator’s travel was “personal and unrelated to any legislative activity.”
The insulin costs $940 in Houston and $24 in Mexico City. The senator’s cancer treatment costs nothing in a country where ASHPA doesn’t apply. The law protects the lawmaker. The law kills the patient.
[This article was archived from Open Net sources. It is not available on Clean Net. Possession of Open Net media may constitute a violation of the Digital Heritage Act.]